PURPOSE: To report successful therapy with gatifloxacin 0.3% ophthalmic solution (Zymar) in a patient with atypical mycobacterium keratitis after penetrating keratoplasty. METHODS: A 58-year-old patient was referred for evaluation of microbial keratitis after penetrating keratoplasty. RESULTS: Clinical examination of the patient revealed an infiltrate at the inferior graft-host junction with a satellite lesion with a mild inflammatory reaction in the anterior chamber. Microbiologic evaluation confirmed the diagnosis of atypical mycobacteria keratitis. The corneal abscess was completely eradicated with a topical course of gatifloxacin 0.3% with preservation of graft clarity and good visual acuity. Topical treatment with gatifloxacin 0.3% was continued for an additional period of 5 months. CONCLUSION: Topical gatifloxacin 0.3% may be successfully used to treat microbial keratitis resulting from atypical mycobacteria.
PURPOSE: To report successful therapy with gatifloxacin 0.3% ophthalmic solution (Zymar) in a patient with atypical mycobacteriumkeratitis after penetrating keratoplasty. METHODS: A 58-year-old patient was referred for evaluation of microbial keratitis after penetrating keratoplasty. RESULTS: Clinical examination of the patient revealed an infiltrate at the inferior graft-host junction with a satellite lesion with a mild inflammatory reaction in the anterior chamber. Microbiologic evaluation confirmed the diagnosis of atypicalmycobacteria keratitis. The corneal abscess was completely eradicated with a topical course of gatifloxacin 0.3% with preservation of graft clarity and good visual acuity. Topical treatment with gatifloxacin 0.3% was continued for an additional period of 5 months. CONCLUSION: Topical gatifloxacin 0.3% may be successfully used to treat microbial keratitis resulting from atypical mycobacteria.